Zarxio

Generic name:filgrastim-sndz
Drug class:Colony stimulating factors
Approval date: March 6, 2015
Company: Sandoz Inc.
Treatment for: Neutropenia Associated with Chemotherapy

Medically reviewed by Drugs.com. Last updated on May 31, 2022.

FDA Approves Zarxio

The United States Food and Drug Administration (FDA) has approved Zarxio (filgrastim-sndz), a leukocyte growth factor biosimilar to the reference product Neupogen. It is indicated for the treatment of neutropenia associated with chemotherapy and all other indications included in the reference product's label.

Patient Information

Read this Patient Information before you start treatment and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is Zarxio?

Zarxio is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body’s fight against infection.

Do not use this medicine if you have had a serious allergic reaction to human G-CSFs such as filgrastim or pegfilgrastim products.

Before you start treatment, tell your doctor about all of your medical conditions, including if you:

• have a sickle cell disorder.
• have kidney problems.
• are receiving radiation therapy.
• are allergic to latex. The needle cap on the prefilled syringe contains natural rubber (derived from latex). Do not handle the prefilled syringe if you are allergic to latex.
• are pregnant or plan to become pregnant. It is not known if this medication will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if this medication passes into your breast milk.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive Zarxio?

• Zarxio injections can be given by a healthcare provider or nurse by intravenous (IV) infusion or under your skin (subcutaneous injection). Your healthcare provider may decide subcutaneous injections can be given at home by you or your caregiver. If the injection is given at home, see the detailed “Instructions for Use” that comes with your prescription for information on how to prepare and inject the dose.
• You and your caregiver will be shown how to prepare and inject Zarxio before you use it.
• Your healthcare provider will tell you how much to inject and when to inject it. Do not change your dose unless your doctor tells you to.
• You should not inject a dose less than 0.3 mL (180 mcg) from the prefilled syringe. A dose less than 0.3 mL cannot be accurately measured.
• If you are receiving Zarxio because you are also receiving chemotherapy, the last dose of Zarxio should be injected at least 24 hours before your next dose of chemotherapy.
• If you miss a dose of Zarxio, talk to your healthcare provider about when you should give your next dose.
• Your healthcare provider will d...